Evidence map›Paper›PMID 31949681›Full record

ArticleInternational journal of clinical and experimental pathology2018

The discordance pattern of molecular sub-types between primary and metastatic sites in Chinese breast cancer patients.

Gaoda Ju, Rongxuan Zhu, Hanting Zhao, Fen Ye, Liaoran Zhang, Chaoyi Lin, Yanqiao Lu, Xiang Zhang, Ning Li, Peng Xue and 2 more

Abstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Gaoda JuDepartment of Oncology, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai, P. R. China.
Rongxuan ZhuDepartment of Oncology, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai, P. R. China.
Hanting ZhaoRenji Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai, P. R. China.
Fen YeRenji Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai, P. R. China.
Liaoran ZhangRenji Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai, P. R. China.
Chaoyi LinRenji Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai, P. R. China.
Yanqiao LuRenji Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai, P. R. China.
Xiang ZhangLester and Sue Smith Breast Center, Department of Molecular and Cellular Biology, McNair Medical Institute, Baylor College of Medicine USA.
Ning LiDepartment of Oncology, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai, P. R. China.
Peng XueDepartment of Oncology, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai, P. R. China.
Lifei ZhuDepartment of Oncology, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai, P. R. China.
Hongxia WangDepartment of Oncology, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai, P. R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveBased on estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor (HER-2), and proliferation cell nuclear antigen (Ki-67) status, breast cancer (BC) can be divided into several molecular sub-types. The patterns of these biological receptors may change during the course of progression and metastasis which could lead to new treatment strategies accordingly.

methodThe present multi-center-based clinical data investigated the discordance patterns of molecular features in Chinese BC patients between primary tumors and distant metastasis. 151 pathologically confirmed BC patients were enrolled. The comparison of the statuses of ER, PR, HER-2, and the Ki-67 index by the IHC and/or FISH method was performed.

resultsThe discordance rate in one or more molecular markers was 52.4% and varied between primary and metastatic lesions. The most common transformation pattern was the loss of ER and PR. On the other hand, the ER-positive patients have the longest OS. Patients with ER changing from positive to negative have the shortest OS. The patients with PR changing from negative to positive have the longest OS, while PR-negative patients have the shortest OS. The median DFI (disease-free interval) was 54.93 months in this study. ER, PR, and HER-2 transformation rates are common in patients with DFI < 2 years than in patients with DFI ≥ 5 years. For patients with an ER-positive expression in metastatic lesions, a significantly prolonged PFS was observed (P < 0.05) in those receiving endocrine treatment.

conclusionThe transformation of molecular subtyping status was identified between primary and corresponding relapse lesions and was used for determining the treatment strategies and prognosis prediction in advanced BC patients.

Indexed as

Breast cancermolecular subtypingre-biopsyrelapse

Identifiers

PMID31949681
PMCPMC6963059

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.